BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?
BAYRY Outperforms Industry, Sector & S&P 500 Index
While challenges in its Crop Science business and litigations have bogged down investors in the past couple of years, 2025 has proved to be a turnaround for Bayer.
The impressive performance can be attributed to new drug approvals and encouraging pipeline progress.
Let's delve further into BAYRY's strengths and weaknesses to analyze how to play the stock at present.
BAYRY's Efforts to Strengthen Pharma Business
Bayer's new products, such as prostate cancer drug Nubeqa and kidney disease drug Kerendia (finerenone), continue to maintain their impressive momentum in the Pharmaceutical division and offset the negative impact of a decline in Xarelto sales.
The FDA recently approved a label expansion of the kidney disease drug Kerendia. The regulatory body approved finerenone for the treatment of adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40%.
With the latest FDA approval, Kerendia has become the only non-steroidal mineralocorticoid receptor antagonist approved in the United States for chronic kidney disease associated with type 2 diabetes and for HF with LVEF of ≥40%.
Last month, the FDA also expanded Nubeqa's label for a third indication for patients with advanced prostate cancer. Following this approval, Nubeqa is the first FDA-approved androgen receptor inhibitor for the treatment of patients with hormone-sensitive prostate cancer, in combination with androgen deprivation therapy, with or without chemotherapy.
In addition, Nubeqa is approved for the treatment of adult patients with non-metastatic castration-resistant prostate cancer, who are at high risk of developing metastatic disease.
We remind investors that Nubeqa achieved blockbuster status in 2024, with annual sales reaching €1.52 billion for full-year 2024.
BAYRY expects to launch two new drugs — elinzanetant, a hormone-free treatment for menopause symptoms, and acoramidis, a drug for the treatment of a certain type of heart disease.
Elinzanetant was recently approved in the UK for the treatment of moderate to severe vasomotor symptoms (VMS or hot flashes) associated with menopause under the brand name Lynkuet. Elinzanetant is under regulatory review in the United States, countries of the European Union and other markets around the world for VMS.
Bayer recently submitted a marketing authorization application to the European Medicines Agency for its investigational contrast agent gadoquatrane for contrast enhancement in magnetic resonance imaging to detect and visualize known or suspected pathologies in all body regions and the central nervous system in adults and pediatric patients, including neonates.
A new drug application has also been submitted to the FDA for gadoquatrane for the above-mentioned indication.
The European Commission has also granted a label extension for Eylea (aflibercept 8 mg, 114.3 mg/ml solution for injection) with extended treatment intervals of up to 6 months for the treatment of two major retinal diseases, neovascular (wet) age-related macular degeneration and visual impairment due to diabetic macular edema.
Please note that Bayer's HealthCare unit co-develops Eylea with Regeneron REGN, which records net product sales of Eylea in the United States. BAYRY records net product sales of Eylea outside the country. REGN records its share of profits/losses in connection with the sales of Eylea outside the United States.
Bayer also has a collaboration agreement with Johnson & Johnson JNJ for oral anticoagulant Xarelto. The drug is marketed by J&J. Bayer earns license revenues from JNJ for Xarelto sales in the United States.
The company also aims to strengthen its pharmaceutical pipeline. In 2021, Bayer acquired the clinical-stage biopharmaceutical company Vividion Therapeutics to expand its presence in precision small-molecule therapeutics, with a primary focus on oncology and immunology.
BAYRY has expanded its pipeline in new modalities of cell therapy through the acquisition of BlueRock, and in gene therapy, through the AskBio buyout.
Cost-Cutting Measures Should Boost BAYRY's Earnings
Bayer has implemented a new operating model to reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes. The company is also undertaking significant job cuts. These efforts should help the company cut costs.
BAYRY's Valuation and Estimates
From a valuation perspective, BAYRY is currently quite inexpensive. Going by the price/earnings ratio, the company's shares currently trade at 5.90X forward earnings, quite below 15.16X for the industry. The stock is trading below its five-year mean of 6.94X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings per share has risen from $1.25 to $1.30 while that for 2026 has increased from $1.31 to $1.35 over the past 60 days.
Invest in BAYRY
Pharma bigwigs are mostly considered safe havens for investors interested in this sector. BAYRY has one of the most diversified portfolios in the industry. The pharma business continues to march ahead. Newer drugs pave the way for growth, and the approval of additional new drugs should further bolster the portfolio.
New launches in the Consumer Health business are a positive.
While challenges for the Crop Science business and significant Roundup litigation charges continue to be a headwind, the company's recent upbeat performance provides distressed investors with a ray of hope.
We recommend the stock to investors at current levels as we believe the worst is most likely behind BAYRY and the company is poised for a turnaround hereafter.
BAYRY currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity.
Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
27 minutes ago
- CTV News
S&P/TSX composite loses steam through the trading day
A person walks past the TMX Market Centre in Toronto, Wednesday, Sept. 11, 2024. THE CANADIAN PRESS/Paige Taylor White TORONTO — Canada's main stock index lost steam throughout the trading day Monday to close just a few points higher, while U.S. markets were mixed. The S&P/TSX composite index was up 2.99 points at 27,317.00. In New York, the Dow Jones industrial average was down 19.12 points at 44,323.07. The S&P 500 index was up 8.81 points at 6,305.60, while the Nasdaq composite was up 78.52 points at 20,974.17. The Canadian dollar traded for 73.03 cents US compared with 72.89 cents US on Friday. The September crude oil contract was down 10 cents US at US$65.95 per barrel. The August gold contract was up US$48.10 at US$3,406.40 an ounce. This report by The Canadian Press was first published July 21, 2025.
Globe and Mail
27 minutes ago
- Globe and Mail
EVgo to Report Second-Quarter 2025 Results on August 5
EVgo Inc. (Nasdaq: EVGO), one of the nation's largest public fast charging networks for electric vehicles (EVs), today announced that it will release its second quarter 2025 financial results on Tuesday, August 5. This release will be followed by a webcast hosted by members of the EVgo management team at 8 a.m. ET (5 a.m. PT). EVgo Second Quarter 2025 Webcast When: Tuesday, August 5 Time: 8 a.m. ET (5 a.m. PT) Live Webcast: A copy of the press release with the financial results and the presentation discussed during the webcast will be available on the Investor Relations section of EVgo's website prior to the commencement of the webcast. An archive of the webcast will be available for a period of time shortly after the call on the Events & Presentations page in the Investor Relations section of EVgo's website. About EVgo EVgo (Nasdaq: EVGO) is one of the nation's leading public fast charging providers. With more than 1,100 fast charging stations across over 40 states, EVgo strategically deploys localized and accessible charging infrastructure by partnering with leading businesses across the U.S., including retailers, grocery stores, restaurants, shopping centers, gas stations, rideshare operators, and autonomous vehicle companies. At its dedicated Innovation Lab, EVgo performs extensive interoperability testing and has ongoing technical collaborations with leading automakers and industry partners to advance the EV charging industry and deliver a seamless charging experience.
Globe and Mail
27 minutes ago
- Globe and Mail
reAlpha Tech Corp. Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
DUBLIN, Ohio, July 21, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (Nasdaq: AIRE) (the 'Company' or 'reAlpha'), an AI-powered real estate technology company, today announced that it has entered into definitive agreements for the purchase and sale of 14,285,718 shares of its common stock at a purchase price of $0.35 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 14,285,718 shares of common stock at an exercise price of $0.35 per share that will be exercisable upon issuance and will expire five years from the effective date of the registration statement covering the resale of the shares of common stock issuable upon exercise of the unregistered warrants. The closing of the offering is expected to occur on or about July 22, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be approximately $5 million. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which could include repayment of debt, future acquisitions, capital expenditures and the purchase of cryptocurrencies in accordance with the Company's cryptocurrency investment policy. The common stock (but not the unregistered warrants and the shares of common stock underlying the unregistered warrants) described above are being offered by the Company pursuant to a 'shelf' registration statement on Form S-3 (File No. 333-283284) that was declared effective by the Securities and Exchange Commission (the 'SEC') on November 26, 2024. The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@ The unregistered warrants described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act'), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying such unregistered warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the unregistered warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About reAlpha Tech Corp. reAlpha Tech Corp. (Nasdaq: AIRE) is an AI-powered real estate technology company transforming the multi-trillion-dollar U.S. real estate services market. reAlpha is developing an end-to-end platform that streamlines real estate transactions through integrated brokerage, mortgage, and title services. With a strategic, acquisition-driven growth model and proprietary AI infrastructure, reAlpha is building a vertically integrated ecosystem designed to deliver a simpler, smarter, and more affordable path to homeownership. For more information, visit Forward-Looking Statements The information in this press release includes 'forward-looking statements.' Any statements other than statements of historical fact contained herein, including statements as to the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'could', 'might', 'plan', 'possible', 'project', 'strive', 'budget', 'forecast', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: reAlpha's ability to regain and sustain compliance with the Nasdaq Capital Market's continued listing standards and remain listed on the Nasdaq Capital Market; reAlpha's ability to pay contractual obligations; reAlpha's liquidity, operating performance, cash flow and ability to secure adequate financing; reAlpha's limited operating history and that reAlpha has not yet fully developed its AI-based technologies; whether reAlpha's technology and products will be accepted and adopted by its customers and intended users; reAlpha's ability to commercialize its developing AI-based technologies; reAlpha's ability to successfully enter new geographic markets; reAlpha's ability to integrate the business of its acquired companies into its existing business and the anticipated demand for such acquired companies' services; reAlpha's ability to scale its operational capabilities to expand into additional geographic markets and nationally; the potential loss of key employees of reAlpha and of its subsidiaries; the outcome of certain outstanding legal proceedings against reAlpha; reAlpha's ability to obtain, and maintain, the required licenses to operate in the U.S. states in which it, or its subsidiaries, operate in, or intend to operate in; reAlpha's ability to successfully identify and acquire companies that are complementary to its business model; the inability to maintain and strengthen reAlpha's brand and reputation; any accidents or incidents involving cybersecurity breaches and incidents; the inability to accurately forecast demand for AI-based real estate-focused products; the inability to execute business objectives and growth strategies successfully or sustain reAlpha's growth; the inability of reAlpha's customers to pay for reAlpha's services; the inability of reAlpha to obtain additional financing or access the capital markets to fund its ongoing operations on acceptable terms and conditions; the outcome of any legal proceedings that might be instituted against reAlpha; changes in applicable laws or regulations, and the impact of the regulatory environment and complexities with compliance related to such environment; and other risks and uncertainties indicated in reAlpha's SEC filings. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. Although reAlpha believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. reAlpha's future results, level of activity, performance or achievements may differ materially from those contemplated, expressed or implied by the forward-looking statements, and there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking statements. For more information about the factors that could cause such differences, please refer to reAlpha's filings with the SEC. Readers are cautioned not to put undue reliance on forward-looking statements, and reAlpha does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
